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Mitochondria are crucial cellular organelles in eukaryotes, and there can be several hundred mitochondria in a sin-gle human cell1. Known as ‘the powerhouses of the cell’, 
mitochondria play essential roles in generating most of the cell’s 
energy through oxidative phosphorylation2. Despite its small size 
(16.6 kilobases (kb)), the circular mitochondrial genome encodes 
13 proteins that form respiratory chain complexes with other 
proteins of nuclear origin3. The involvement of mitochondria in 
carcinogenesis has long been suspected4,5 because altered energy 
metabolism is a common feature of cancer6. Furthermore, mito-
chondria play important roles in other tasks, such as biosynthesis, 
signaling, cellular differentiation, apoptosis, maintaining control 
of the cell cycle and cell growth, all of which are intrinsically linked 
to tumorigenesis5,7.
In several recent studies, molecular characterization of mitochon-
dria was performed in cancer by using next-generation sequencing 
data8–13, but these studies usually describe one specific dimension 
of the mitochondrial genome (for example, somatic mutations) 
based on relatively small sample cohorts. Furthermore, due to the 
whole-exome sequencing data employed, the relatively low depth 
of mitochondrial genomes limits the accuracy and scope of these 
studies. Thus, a comprehensive, multidimensional molecular 
portrait of mitochondria across a broad range of cancer types 
has not been achieved. Moreover, previous studies have focused 
on the patterns of mitochondrial alterations alone, without fully 
exploring the interplay between the mitochondrial genome and 
the nuclear genome, as well as the biomedical significance of mito-
chondrial alterations.
The Pan-Cancer Analysis of Whole Genomes (PCAWG) 
Consortium aggregated whole-genome sequencing (WGS) 
data from 2,658 cancers across 38 tumor types generated by the 
International Cancer Genome Consortium (ICGC) and The Cancer 
Genome Atlas (TCGA) projects. These sequencing data were re-
analyzed with standardized, high-accuracy pipelines to align to the 
human genome (reference build hs37d5) and identify germline vari-
ants and somatically acquired mutations, as described14. Meanwhile, 
TCGA has generated RNA sequencing (RNA-seq) data from a large 
number of patient samples, which allow for assessment of the tran-
scriptional activities of mitochondrial genes15. These large-scale 
datasets create a tremendous resource for characterizing cancer 
mitochondrial genomes at an unprecedented level (Fig. 1a). We first 
characterized mitochondrial somatic mutations, nuclear transfers 
and copy numbers, then investigated their interactions with nuclear 
somatic alterations16,17, and finally examined the expression profiles 
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Mitochondria are essential cellular organelles that play critical roles in cancer. Here, as part of the International Cancer Genome 
Consortium/The Cancer Genome Atlas Pan-Cancer Analysis of Whole Genomes Consortium, which aggregated whole-genome 
sequencing data from 2,658 cancers across 38 tumor types, we performed a multidimensional, integrated characterization 
of mitochondrial genomes and related RNA sequencing data. Our analysis presents the most definitive mutational land-
scape of mitochondrial genomes and identifies several hypermutated cases. Truncating mutations are markedly enriched in 
kidney, colorectal and thyroid cancers, suggesting oncogenic effects with the activation of signaling pathways. We find fre-
quent somatic nuclear transfers of mitochondrial DNA, some of which disrupt therapeutic target genes. Mitochondrial copy 
number varies greatly within and across cancers and correlates with clinical variables. Co-expression analysis highlights the 
function of mitochondrial genes in oxidative phosphorylation, DNA repair and the cell cycle, and shows their connections with 
clinically actionable genes. Our study lays a foundation for translating mitochondrial biology into clinical applications.
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Fig. 1 | Mutational landscape and process of cancer mitochondrial genomes. a, Overview of our multidimensional and integrated mitochondrial genome 
analyses. b, Landscape of mtDNA somatic substitutions. The numbers represent the mitochondrial genome coordinates. The outer (blue) circle shows 
the density of all variants with VAF > 1%. The inner (red) circle shows the density of variants with VAF > 3%. c, Highly consistent mtDNA mutational 
spectrum across 21 cancer tissue groups. Average numbers of somatic substitutions per sample are also shown (right). d, Correlation between the 
highest VAF of mtDNA mutations in a cancer tissue and patient age at the time of diagnosis. The correlation was based on the 2,414 patients with both 
age and somatic single-nucleotide variant information available. The shaded region represents the 95% confidence interval for the predictions from a 
linear model with the highest VAF as the response variable and patient age as the explanatory variable. e, Correlations between the numbers of nuclear 
and mtDNA somatic mutations. The associations were tested among samples with both nuclear and mtDNA somatic mutations available (with sample 
sizes labeled on plot) using Spearman’s rank correlation. Magenta bars indicate significant positive correlations (P < 0.05). Asterisks indicate that both 
nuclear and mitochondrial somatic mutations were correlated with patient age in that cancer type (P < 0.05). f, Proportions of tumor samples harboring 
different categories of somatic alterations: nuclear driver alterations only (red); both nuclear driver alterations and mtDNA mutations (VAF > 10%, 
green); and mtDNA mutations without known nuclear drivers (blue). AML, acute myeloid leukemia; BNHL, B cell non-Hodgkin lymphoma; CA, carcinoma; 
ChRCC, chromophobe renal cell carcinoma; CLL, chronic lymphocytic leukemia; CNS, central nervous system; eso, esophageal; GBM, glioblastoma; 
HCC, hepatocellular carcinoma; leiomyo, leiomyosarcoma; liposarc, liposarcoma; medullo, medulloblastoma; MPN, myeloproliferative neoplasm; oligo, 
oligometastatic; osteosarc, osteosarcoma; PiloAstro, pilocytic astrocytoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; TCC, transitional 
cell carcinoma; adenoCA, adenocarcinoma; epith, epithelioid.
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of mitochondrial genes and their connections with clinically rel-
evant nuclear genes.
results
Mutational landscape of cancer mitochondrial genomes. To char-
acterize somatic mutations in mitochondrial genomes across can-
cer types, we extracted the mitochondrial DNA (mtDNA) mapped 
reads of 2,658 cancer and matched control sample pairs from the 
PCAWG Consortium. The samples we surveyed covered 21 cancer 
tissues and 38 specific cancer types (Supplementary Table 1). On 
average, the sequencing depth for the mitochondrial genome was 
9,959×, which was much higher than that obtained from whole-
exome sequencing data, allowing for confident detection of somatic 
mutations at a very low heteroplasmic level (variant allele fraction 
(VAF) > 1%; Supplementary Fig. 1). By applying a well-designed 
computational pipeline that carefully considered various poten-
tially confounding factors (for example, sample cross-contamina-
tion, mismapping of reads from nuclear mtDNA-like sequence18, 
and artifactual mutations caused by oxidative DNA damage dur-
ing library preparation19), we identified a total of 7,611 somatic 
substitutions and 930 small indels in 2,536 high-quality cancer 
samples (122 samples were excluded in the mutation analysis for 
the issues mentioned above; Supplementary Fig. 2 and Methods). 
The high reliability of the mutations was confirmed by long-range 
PCR-based validation (Supplementary Table 2) and by inspection of 
the mutational spectrum of the very low-VAF mutation candidates 
(Supplementary Fig. 3).
Of the 7,611 substitutions, >85% were clearly heteroplas-
mic, showing VAFs lower than 0.6 (average: 0.2; median: 0.045). 
Overall, mtDNA mutations located in the transcribed regions were 
also found in RNA-seq with similar VAFs, except for a fraction of 
transfer RNA (tRNA) mutations showing much higher VAFs in 
transcripts due to the accumulation of unprocessed tRNA precur-
sors during the processing of polycistronic mitochondrial tran-
scripts10 (Supplementary Fig. 4). Across all of the cancer samples, 
we observed several mutational hotspots in the regulatory D-loop 
region and the ND4 gene (Fig. 1b). Of the 13 protein-coding genes, 
ND5 was the most frequently mutated in most cancer types, while 
ND4 was most frequently mutated in prostate and lung cancers, 
and COX1 was most frequently mutated in breast, cervical and 
bladder cancers (Supplementary Fig. 5). We identified that can-
cer type and gene identity were associated with the mutation sta-
tus of the 13 coding genes (log-linear model, Pcancer type < 2.2 × 10−16; 
Pgene < 2.2 × 10−16), but the effect of their interaction was not signifi-
cant (Pcancer type × gene = 0.12).
In contrast with somatic mutations in nuclear genomes (where 
cancer type-specific mutational signatures are observed)20, mtDNA 
mutational signatures were very similar across tumor types, with 
C:G>T:A (58.3%) and T:A>C:G (34.2%) substitutions being the 
most and second most frequent mutation types, respectively (Fig. 1c 
and Supplementary Fig. 6). Indeed, the impact of well-known car-
cinogens (for example, tobacco smoking (C:G>A:T dominant; 
signature 4), ultraviolet light (C:G>T:A dominant at dipyrimi-
dine contexts; signature 7) and reactive oxygen species (G:C>T:A 
dominant)) were minimal (Supplementary Fig. 7) even in lung and 
skin cancers (the latest mutational signatures of nuclear genomes 
are available from the Catalogue of Somatic Mutations in Cancer 
database: https://cancer.sanger.ac.uk/cosmic/signatures). Instead, 
the vast majority of mtDNA mutations were manifesting extreme 
replicational mtDNA strand bias9,21,22; that is, predominant G>A 
and T>C substitutions and deficient complementary C>T and 
A>G substitutions on the light (L) strand of the mtDNA genome 
sequence (+strand of the revised Cambridge Reference Sequence) 
despite the relative depletion of guanines and thymines on the 
L strand (Supplementary Fig. 6). These mutational signatures sug-
gest that mitochondria-specific, replication-coupled mutational 
processes (such as mtDNA polymerase gamma error9,21,23 or other 
replication-coupled DNA damage mechanisms) are dominantly 
responsible for somatic mtDNA mutations in cancer.
In agreement with its endogenous origin, we observed clock-like 
properties in mtDNA mutations as nuclear genome mutations24. 
The number of mtDNA mutations in our study was largely pro-
portional to the age of the patient at the time of tissue sampling 
(Supplementary Fig. 8). In addition, the maximum VAF of somatic 
mutations in a cancer tissue showed positive correlation with age, 
on average (Fig. 1d; P < 2.2 × 10−16). Collectively, these results sug-
gest that the vast majority of mtDNA somatic mutations were: 
(1) acquired at an earlier age when the cell lineage was phenotypi-
cally normal; and (2) overall shifted towards homoplasmy through-
out life in the cellular lineage of the neoplastic cells. The spread 
to homoplasmy can, in theory, be caused by either physiological 
advantage (selection) or a series of asymmetric segregations during 
cell divisions (drift)25, or both.
To further assess the potential impact of mtDNA mutations, 
we performed integrative analysis by examining alterations from 
mitochondrial and nuclear genomes simultaneously17. We observed 
significantly positive correlations between the mutation burdens of 
mitochondrial and nuclear genomes in several cancer types, with 
the highest correlations observed in kidney chromophobe and thy-
roid cancers (magenta bars in Fig. 1e). Some of these correlations 
may be explained by the age effect, as the mutation numbers in both 
mitochondrial and nuclear genomes were significantly correlated 
with patient age in the corresponding cancer types (bars marked 
with an asterisk in Fig. 1e). In addition, we examined the mtDNA 
mutation frequency in the context of nuclear drivers. Although 
nuclear driver alterations exist in the majority of patients in most 
cancer types, a notable proportion of patients (22.2% with kidney 
chromophobe cancer and 18.8% with thyroid cancer) bear non-
silent mtDNA mutations but no known nuclear drivers, suggest-
ing a potential functional contribution of mtDNA mutations in the 
absence of nuclear drivers in these cancer types (Fig. 1f).
Hypermutation process in mitochondrial genomes. Hyperm-
utation processes have been well established for a small proportion 
of cancer nuclear genomes (for example, microsatellite instabil-
ity)26,27, but have not been reported for mitochondrial genomes. Of 
the 2,536 cancer samples surveyed, seven cases showed extremely 
large numbers of mtDNA somatic substitutions (>13 mutations), 
which were larger than expected from the background distribution 
(Fig. 2a; around three somatic substitutions per sample on average, 
with a standard deviation of 2.6). The mutational spectra in these 
hypermutated samples were sometimes clearly distinguished from 
the background L-strand G>A and T>C substitution dominant sig-
nature (Fig. 2b), suggesting that the massive numbers of mutations 
are not the consequence of the gradual accumulation of ordinary 
mtDNA substitutions.
The most striking case was a breast cancer sample (sample ID: 
SP6730) harboring 33 mutations, 30 of which were localized in a 
2-kb region (Fig. 2c), resulting in a local hypermutational rate 
(>75× higher than the background mutational rate). The mutations 
were neither of germline origin (~70% were novel) nor caused by 
sequencing errors, as confirmed by independent exome and RNA-
seq analyses (Supplementary Fig. 9). Interestingly, most of the local-
ized mutations (n = 28) were T>C substitutions on the L strand 
(Fig. 2b,c) and were co-clonal of each other, with highly similar 
VAFs (~7%) and direct physical phasing by Illumina sequencing 
reads (Supplementary Fig. 9). Collectively, these lines of evidence 
strongly suggest that the 28 localized mutations (19 missense, four 
silent and five tRNA mutations) were acquired by a ‘single-hit’ 
catastrophic mutational mechanism with strand-specific T>C sub-
stitutions as a dominant spectrum, reminiscent of the kataegis phe-
nomenon in the nuclear genome28 (Fig. 2c) and/or complex somatic 
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mutations reported in mtDNA29. The mutated mtDNA copy is then 
likely to shift to appreciable VAF (~7% frequency) by a series of rep-
lications throughout the cell lineages, despite the low probability of 
causation of a defective phenotype.
Cancer type-specific selective pressures on mtDNA mutations. 
To investigate the functional consequences of mtDNA genes, we 
examined the dN/dS ratio (a common measure of selective pressure 
on missense mutations) with consideration of the unique mtDNA 
mutational signature9. We found that dN/dS was overall close to 1 
for missense mutations at different VAFs across cancer types, sug-
gesting that overall selection for mtDNA missense mutations is 
nearly neutral (Supplementary Fig. 10). However, it should not be 
interpreted that all missense mtDNA mutations are passengers.
For truncating mutations on the 13 mtDNA genes, we found 
evidence of negative selection in most cancer types, suggesting the 
importance of intact mitochondrial function in cancer cells. For 
example, the VAFs of mtDNA truncating mutations were notably 
more suppressed than those of missense or silent mutations (Fig. 3a). 
Interestingly, kidney, colorectal and thyroid cancers showed the 
opposite trend, where mtDNA truncating mutations exhibited sig-
nificantly higher VAFs than the background (F-test, P < 2.2 × 10−16; 
Fig. 3a). The enrichment of nearly homoplasmic (>60% VAF) trun-
cating mutations was very striking in kidney cancers, especially 
in chromophobe and papillary types, suggesting that the inactiva-
tion of the normal mitochondrial function is an important step in 
tumorigenesis30 (Fig. 3b and Supplementary Fig. 11). The mtDNA 
truncating mutations were enriched in ND5. Compared with 
kidney chromophobe and colorectal cancers, kidney papillary can-
cers harbored ND5 truncation mutations enriched in the amino-
terminal region (Fisher’s exact test, P = 0.05; Fig. 3c). Integrating 
with the mutation data of nuclear genes, we found that the high VAF 
truncating mutations in the two kidney cancer types were mutu-
ally exclusive to the mutations of known cancer genes (Fisher’s exact 
test, P = 0.01; Fig. 3d). Moreover, samples with mtDNA truncating 
mutations showed upregulation of gene expression in cancer-related 
pathways, such as mammalian target of rapamycin signaling, tumor 
necrosis factor-α signaling, oxidative phosphorylation and protein 
secretion (false discovery rate (FDR) < 0.05; Fig. 3e). Collectively, 
these results strongly suggest functional oncogenic impacts of mito-
chondrial truncating mutations in the initiation and clonal evolu-
tion of the specific cancer types.
Somatic transfer of mtDNA into the nuclear genome. The migra-
tion of mtDNA into the nuclear genome has been assessed using 
different technologies31–33. Recently, somatic mtDNA nuclear trans-
fers (SMNTs) have been more systematically studied in nucleotide 
resolution11, mostly in breast cancers. In this study, of the 2,658 can-
cer cases across 21 tissue types, we found 55 positive cases (2.1% 
overall positive rate) (Methods). The SMNT rate varied according 
to the cancer tissue type (Fisher’s exact test, P < 1 × 10−5; Fig. 4a). 
For example, lung, skin, breast and uterine cancers showed frequen-
cies higher than 5%. In particular, human epidermal growth factor 
receptor 2-positive (HER2+) breast cancers and squamous cell lung 
cancers showed positive rates of 16.0% (four out of 25 cases) and 
14.6% (seven out of 48 cases), respectively, which were significantly 
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Fig. 2 | Characterization of hypermutated cancer mitochondrial genomes. a, Distribution of mtDNA mutations. The blue curve represents the 
calculated ratio between observed and expected numbers of samples for each bin (right-hand y axis). b, Mutational spectrum of the seven hypermutated 
mitochondrial genomes identified. The P values were generated by chi-squared test without multiple comparison adjustment (**P < 0.01; ****P < 0.0001). 
c, Distribution of the 33 somatic mutations in the breast cancer sample of mtDNA hypermutation (sample ID: SP6730). d, Proposed model of the mtDNA 
hypermutation process in SP6730. rRNAs, ribosomal RNAs.
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Fig. 3 | mtDNA truncating mutation patterns. a, Distinct VAF accumulation curves of truncating mutations between kidney/colorectal/thyroid cancers and 
other cancer types. For comparison, similar curves were generated for silent and missense mutations, which are overall functionally neutral, in other types of 
cancer after normalization of mutation numbers. Generally, fewer truncating mutations were observed at higher allele-frequency levels (red), except for kidney, 
colorectal and thyroid cancer types (blue). n = number of samples. b, Kidney chromophobe, kidney papillary, colorectal and thyroid cancers accumulated 
excessive high-allele-frequency truncating mutations (sample sizes in parentheses). Areas under the curve across cancer types for a VAF interval of 0.6–1.0 
(from Supplementary Fig. 11a); were calculated and are shown. Their distribution is shown by a box plot. The boundaries of the box mark the first and third 
quartile, with the median in the center, and whiskers extending to 1.5× the interquartile range from the boundaries. c, Distribution patterns of truncating 
mutations in ND5. C, carboxy; N, amino; Proton_antipo_N, NADH-ubiquinone oxidoreductase (complex I), chain 5 N-terminus; Proton_antipo_M, proton-
conducting membrane transporter; NADH5_C, NADH dehydrogenase subunit 5 C terminus. d, Heat map of mtDNA truncating mutations with recurrent 
somatic mutations in cancer genes in kidney chromophobe and kidney papillary cancers. MT_truncating standas for mitochondrial truncating mutations, which 
include frameshift mutations and stop-gain mutations. Statistical significance of mutual exclusivity between mutations was assessed by Fisher’s exact test. 
SNV, single-nucleotide variant. e, Heat map of the signaling pathways enriched by nuclear genes upregulated in cancer samples with truncating mutations.  
A dot indicates FDR < 0.05. IFN-γ, interferon-γ; IL-6, interleukin-6; JAK, Janus kinase; mTORC1, mammalian target of rapamycin complex 1; NF-κB, nuclear 
factor κB; STAT3, signal transducers and activators of transcription 3; TNF-α, tumor necrosis factor-α; KRAS, KRAS proto-oncogene, GTPase.
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higher than the average (Fisher’s exact test, P < 0.003 and P < 0.001, 
respectively). In contrast, we did not find any positive cases from 
blood, kidney, esophagogastric, liver, prostate and colorectal can-
cers. The samples with SMNTs showed a much higher number of 
global and local structural variations in the nuclear genome than the 
control samples16 (P = 1 × 10−4; Fig. 4b and Supplementary Fig. 12). 
SMNT integration sites (breakpoints) were spatially closer to inver-
sion and translocation breakpoints than expected (Fig. 4c). These 
results suggest that the integration of mtDNA segments into nuclear 
DNA is often mechanistically combined with some specific pro-
cesses underlying structural variations in the nuclear genome.
Despite the overall low SMNT frequency (~2%), some cancer 
samples showed up to three independent SMNT events (Fig. 4d and 
Supplementary Fig. 13). Sometimes, somatically transferred mtDNA 
segments were extensively rearranged (Supplementary Fig. 13b), 
implying extreme genomic instability at the time of the SMNT 
events. We observed 42 SMNT events in 35 tumor cases that were 
integrated in the middle of genes (n = 42), mostly in introns (n = 37), 
with a few events in the protein-coding regions (n = 3) and in the 
untranslated regions (n = 2) (Supplementary Table 3). Among these, 
open reading frames of at least 23 genes (23/42 = 55%), including 
cancer genes such as ERBB2, FOLH1 and ULK2, were predicted to 
be altered by these SMNTs and their combined structural variant 
events in the vicinity (Supplementary Fig. 14). Of particular inter-
est, one SMNT was involved in transforming focal amplification of 
the ERBB2 gene in a HER2+ breast cancer genome (Fig. 4e).
Copy-number and structural variations of mtDNA. Although 
previous studies have examined mtDNA copy numbers in individ-
ual cancer types34–36 or from a collection of whole-exome sequenc-
ing data12, we performed a systematic and accurate analysis of 
mtDNA copy numbers per cell over the largest sample cohort with 
WGS data so far, with consideration to confounding factors such as 
the normal-cell contamination and genome ploidy of tumor cells 
(Supplementary Fig. 15 and Methods).
Based on the 2,157 cancer samples that passed the purity filter, we 
observed great variation in mtDNA copy numbers across and within 
cancer types: mtDNAs were most abundant in samples of ovarian 
cancer (median: 644 copies per cell) and least abundant in myeloid 
cancer (median: 90 copies per cell) (Fig. 5a). Different cancer sub-
types originating from the same tissue sometimes showed distinct 
mtDNA copy-number distributions (Fig. 5b and Supplementary 
Fig. 16). For example, the mtDNA copy numbers for kidney chro-
mophobe were significantly higher than those for kidney clear cell 
and kidney papillary (analysis of variance (ANOVA), P < 7.8 × 10−6; 
Fig. 5b). This may be interlinked with the general inadequacy of 
mitochondrial quality control and resultant increase in the steady-
state mtDNA copy number, as seen in renal oncocytoma37. Indeed, 
we found that the mtDNA copy number was significantly higher 
in the samples with high-allele-frequency truncating mutations 
(ANOVA with consideration of confounders, P < 1.7 × 10−4; Fig. 5c), 
suggesting that the dosage effect of mtDNAs was selected to 
compensate for the deleterious effect of truncating mutations. For 
the cancer samples with WGS data from matched normal tissues 
(n = 507), we observed increased mtDNA copy numbers in cancer 
samples in patients with chronic lymphocytic leukemia, lung squa-
mous cell carcinoma and pancreatic adenocarcinoma, but decreased 
copy numbers in cancer samples in patients with kidney clear cell 
carcinoma, hepatocellular carcinoma and myeloproliferative neo-
plasm (Fig. 5d). At face value, the distinct patterns in different 
cancer types may be due to cancer-specific oncogenic stimulation, 
metabolic activity and mitochondrial malfunctions. For example, a 
recent study12 suggested that significantly decreased mtDNA copy 
number in kidney clear cell cancer may be due to downregulation 
of peroxisome proliferator-activated receptor-γ coactivator 1α (a 
central regulator of mitochondrial biogenesis) by hyperactivated 
hypoxia-inducible factor 1α, which is most frequently mutated and 
activated in this disease38. However, since the available mtDNA 
copy numbers in normal tissues are average values from mixtures 
of many heterogeneous cell types with unknown relative contribu-
tions, a direct comparison between tumor and adjacent normal tis-
sues should be interpreted cautiously.
To assess the potential biomedical significance of mtDNA copy 
numbers, we examined their correlations with key clinical variables. 
We found significant positive correlations between the mtDNA copy 
number and the patient’s age at diagnosis in prostate (Spearman’s 
rank, Rs = 0.31; P < 1.7 × 10−4; Fig. 5e), colorectal and skin cancers 
(Supplementary Fig. 17). In contrast, we observed negative corre-
lations of normal blood mtDNA copy number with patient age in 
most cases (Supplementary Fig. 18). We further observed correla-
tions between mtDNA copy number and tumor stage in multiple 
cancer types (Fig. 5f and Supplementary Fig. 19).
Using WGS data, we examined the focal copy gain and loss in 
the mitochondrial genomes that were known to be present in pros-
tate cancers and aged tissues39. Of the 2,658 cancer samples, three 
(0.11%) showed notable structural variants in the mtDNA (Fig. 5g). 
For example, a pancreatic cancer case (sample ID: SP76017) har-
bored a ~3.4-kb-long mtDNA loss that truncated ribosomal RNA 
and ND1 genes. The VAF of this mutant mtDNA was estimated at 
63%. Similarly, a melanoma case (sample ID: SP127680) showed 
tandem duplication of an mtDNA segment of ~4 kb, with 100% 
VAF. Thus, our analysis identified structural variants in mtDNA 
genomes based on WGS.
Co-expression network analysis of mitochondrial genes. To 
understand the functional impact of 13 mtDNA genes in cancers, we 
quantified the gene expression levels using RNA-seq data profiled 
from 4,689 TCGA tumor samples of 13 cancer types (Supplementary 
Table 4). The correlation between the gene expression levels and 
the mtDNA copy number varied by cancer type (Supplementary 
Fig. 20). Among the cancer types, the mtDNA genes were highly 
expressed in the three types of kidney cancer (chromophobe, papil-
lary and clear cell) but weakly expressed in the three types of squa-
mous cell carcinoma (cervical, lung and head and neck) (Fig. 6a). 
Fig. 4 | Somatic transfer of mtDNA into the cancer nuclear genome. a, Frequency of SMNTs in different cancer tissues. Circle size indicates the sample 
size of a given cancer type. ER, estrogen receptor. b, Numbers of structural variant breakpoints in samples with and without SMNTs. Sample sizes are 
labeled below the boxes. The P values (***P < 0.001; ****P < 0.0001) were generated by two-sided t-test without multiple comparison adjustment.  
c, Distances from SMNT breakpoints to the nearest structural variant breakpoints are shorter than random expectation for all and each type of structural 
variant. Sample sizes are labeled in the centers of the boxes. The P values (**P < 0.01; ***P < 0.001) were generated by two-sided t-test without multiple 
comparison adjustment. bp, base pair; exp, expected; Mb, megabase; NS, not significant; obs, observed. d, Circos plot of three independent SMNT events 
in a bladder cancer genome (sample ID: SP953), showing 23 human chromosomes in the outer layer, as well as copy numbers of nuclear cancer genomes 
(inner layer; black dots); chromosomal rearrangements (gray curves) and SMNTs (red curves). A summary of three SMNTs with genomic coordinates in 
numbers is depicted below the Circos plot with breakpoints. e, An SMNT event found in a HER2+ breast cancer genome (sample ID: SP10563), leading 
to a tandem duplication process of ERBB2 exons 10–23 and their subsequent expression. The novel exon junction is supported by the RNA reads from the 
corresponding RNA-seq data. In all boxplots, the boundaries of the boxes mark the first and third quartiles, with the median in the center, and whiskers 
extending to 1.5× the interquartile range from the boundaries.
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This observation was partially due to the relative abundance of 
mtDNA copy number across cancer types and is consistent with a 
study of normal tissues40.
To gain more insight into the functions of mtDNA genes 
and their related nuclear genes and pathways, for each can-
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Fig. 5 | Pan-cancer view of mtDNA copy number. a, Distributions of mtDNA copy number by cancer tissue type. Sample numbers with mtDNA copy-
number information available are labeled on the top, with the median mtDNA copy numbers marked as red bars. b, Distinct mtDNA copy-number 
distributions for cancer types derived from the kidney (top) and brain (bottom). n = number of samples with mtDNA copy number. P values were 
generated by ANOVA. c, mtDNA copy numbers with and without truncating mutations in mtDNA genes. n = number of samples with both mtDNA copy 
number and somatic mutation information available. P values were based on ANOVA, adjusting for cancer types. d, Paired copy-number comparison of 
tumor and matching normal tissue samples. n = number of matching normal tissue and cancer sample pairs. Raw P values were determined by two-sided 
Wilcoxon signed-rank test, then adjusted for FDR (**FDR < 0.01; ***FDR < 0.001). e, Correlation of mtDNA copy number with patient age in prostate 
cancer. n = number of samples with cancer mtDNA copy number and patient age information available. Correlations and P values are based on Spearman’s 
rank correlation. f, Correlation of mtDNA copy number with cancer stage in chronic lymphocytic leukemia. n = number of samples with mtDNA copy 
number and stage information. g, Focal copy gain and loss caused by structural variations in three cancer samples. Green lines represent focal loss, 
whereas red lines represent tandem duplication. In all boxplots, the boundaries of the boxes mark the first and third quartile, with the median in the center, 
and whiskers extending to 1.5× the interquartile range from the boundaries.
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analysis (WGCNA) package41 to build a weighted gene co-expres-
sion network that consisted of both nuclear genes and mitochon-
drial genes (Methods). We then performed gene set enrichment 
analysis (GSEA)42 based on the rank of all nuclear genes by mea-
suring their edge strength to a mitochondrial gene in the co-
expression network. We found oxidative phosphorylation to be 
the top-ranked enriched pathway, and to be enriched in eight 
out of the 13 cancer types examined (FDR < 0.05), highlighting 
the essential role of mitochondrial genes in energy generation 
(Fig. 6b). Pathways related to the cell cycle (MYC targets, mitotic 
spindle, G2/M checkpoint and E2F targets) and DNA repair were 
also enriched in multiple cancer types (Fig. 6b), consistent with 
the established notion that mtDNA plays an important role in 
these pathways37,43.
We also examined the mtDNA-centric co-expression networks 
(Fig. 6c and Methods). Across cancer types, the mtDNA genes were 
almost always strongly interconnected, which is expected since 
they are transcribed as long polycistronic precursor transcripts44. 
Interestingly, several clinically actionable genes were among the 
neighboring genes that showed strong co-expression patterns with 
mtDNA genes (Fig. 6c and Supplementary Fig. 21). For example, 
AR, EGFR, DDR2 and MAP2K2 were connected with mtDNA genes 
in prostate cancer, and TMPRSS2, NF1, PIK3CA, BRCA1 and TOP1 
















































































































































































































































































































































































































Fig. 6 | Co-expression patterns of mtDNA genes across different cancer types. a, Left: heat map of the expression levels of 13 mtDNA genes of 13 cancer 
types. Right: bar plot showing the sample sizes for each cancer type. b, Commonly enriched pathways identified by co-expression with mtDNA genes in 
different cancer types. Borders of cells with FDR < 0.05 are highlighted in yellow. c, mtDNA gene-centric pan-cancer co-expression network. The pie chart 
colors at each node indicate occurrence of the node in cancer types of the corresponding colors. Green borders, nuclear genes; blue borders, mitochondrial 
genes. Node size is proportional to the number of direct neighbors (connectivity) of the node. Thickness of the edge is proportional to the frequency of this 
edge being observed across all cancer types. Edges are colored according to the connection type (gray: mtDNA gene–mtDNA gene connection; magenta: 
mtDNA gene–nuclear gene connection). BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma 
and endocervical adenocarcinoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; 
KIRP, kidney renal papillary cell carcinoma; LGG, brain lower-grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung 
squamous cell carcinoma; PRAD, prostate adenocarcinoma; THCA, thyroid carcinoma.
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This correlation-based analysis does not necessarily suggest causal-
ity, and further efforts are needed to investigate these relationships. 
Elucidating the underlying mechanisms may lay a foundation for 
developing mtDNA-related cancer therapy.
An open-access Cancer Mitochondrial Atlas data portal. To facili-
tate mitochondria-related biological discoveries and clinical appli-
cations, we developed an open-access, user-friendly data portal, 
The Cancer Mitochondrial Atlas (TCMA), for fluent exploration 
of the various types of molecular data characterized in this study 
(Supplementary Fig. 22). The data portal can be accessed at http://
bioinformatics.mdanderson.org/main/TCMA:Overview. There are 
four modules in TCMA: somatic mutations, nuclear transfer, copy 
number and gene expression. The first three modules are based 
on the ICGC WGS data and provide detailed annotations for the 
corresponding features of each cancer sample. The last module is 
based on TCGA RNA-seq data and provides an interactive inter-
face through which users can visualize the co-expression network 
with convenient navigation and zoom features. Not only can users 
browse and query the molecular data by cancer type, they can also 
download all of the data for their own analysis.
Discussion
This work characterizes the cancer mitochondrial genome in a 
comprehensive manner, including somatic mutations, nuclear 
transfer, copy number, structural variants and mtDNA gene expres-
sion. Because of the ultra-high coverage of mtDNA from the WGS 
data and the large number of patient samples surveyed, our study 
provides a definitive landscape of mtDNA somatic mutations and 
identifies several unique features. First, we report hypermutated 
mitochondrial cases, highlighting the dynamic mutational processes 
in this tiny genome. Second, our systemic analysis of mitochondrial 
genomes has firmly shown that several cancer types are enriched 
for high-allele-frequency truncating mutations, including previ-
ously reported kidney chromophobe30,45 as well as newly identified 
kidney papillary, and thyroid and colorectal cancers. Interestingly, 
the thyroid and kidney are the most frequent sites of oncocytomas, 
which are rare, benign tumors characterized by frequent nuclear 
chromosomal aneuploidy as well as vast accumulation of defec-
tive mitochondria45,46, further assuring the functional association 
between mitochondrial inactivation and the pathogenesis of these 
cancer types. Third, in contrast with the diversified mutational 
signatures observed in the nuclear genomes of different cancers20, 
mtDNAs show very similar mutational signatures regardless of 
cancer tissue origins: predominantly G>A and T>C substitutions 
on the L strand. This monotonous pattern may partially stem from 
different mutational generators and DNA repair processes between 
the nucleus and mitochondria9,47,48. Due to their large numbers of 
copies per cell, mitochondria may simply remove mtDNA damaged 
from external mutagens (for example, ultraviolet radiation, tobacco 
smoking and reactive oxygen species) through autophagy and other 
mitochondrial dynamic mechanisms49, rather than employing a 
complex array of repair proteins as in the nucleus.
One unique aspect of our study is the integrative analysis of mito-
chondrial molecular alterations with those in the nuclear genome 
that are characterized by the PCAWG Consortium. We found that: 
(1) high-allele-frequency truncating mtDNA mutations are mutu-
ally exclusive to mutated cancer genes in kidney cancer; (2) mtDNA 
nuclear transfers are associated with increased numbers of struc-
tural variants in the nuclear genome; and (3) mtDNA co-expressed 
nuclear genes are enriched in several processes critical for tumor 
development. These results indicate that the mitochondrial genome 
is an essential component in understanding the complex molecular 
patterns observed in cancer genomes and helping to pinpoint poten-
tial cancer driver events. Our results, such as the nuclear transfer of 
mtDNA into a therapeutic target gene, correlations of mtDNA copy 
numbers with clinical variables, and the co-expression of mtDNA 
and clinically actionable genes, underscore the clinical importance 
of mitochondria.
Taken together, this study has untangled and characterized the 
full spectrum of molecular alterations of mitochondria in human 
cancers. Our analyses have provided essentially complete cata-
logs of somatic mtDNA alterations in cancers, including substi-
tutions, indels, copy-number alterations and structural variants. 
Furthermore, we have developed a user-friendly web resource to 
enable the broader biomedical community to capitalize on our 
results. These efforts lay a foundation for translating mitochondrial 
biology into clinical investigations.
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Methods
Data generation and collection. We extracted BAM files of mtDNA sequencing 
reads from the whole-genome alignment files of 2,658 cancer samples and their 
matched normal tissue samples generated by the PCAWG Consortium. BWA 
was used to align the reads to the human reference genome (hs37d5). From the 
CGHub, we obtained TCGA RNA-seq BAM files of 13 cancer types, all of which 
employed paired-end sequencing strategies. We used Cufflinks to quantify the 
messenger RNA expression levels (in fragments per kilobase per million mapped 
fragments) of the 13 mitochondrial protein-coding genes. We obtained the 
nuclear somatic mutations and annotated driver mutations of corresponding 
samples as described17.
Somatic mutation calling. The nuclear genome mutations were called using 
the Sanger pipeline, provided by the PCAWG. The mitochondrial variants were 
initially called using VarScan2 (ref. 50) and the same parameter setting as previously 
reported9: --strand-filter 1 (mismatches should be reported by both forward 
and reverse reads), --min-var-freq 0.01 (minimum VAF 1%), --min-avg-qual 20 
(minimum base quality 20), --min-coverage × and --min-reads2 ×). We applied 
a series of downstream bioinformatic filters to further remove false positives as 
follows (Supplementary Fig. 2a).
First, we filtered germline polymorphisms and false positive calls (for example, 
frequent mapping errors due to known mtDNA homopolymers, candidates with 
substantial mapping strand bias and candidates with substantial mutant alleles 
in the matched normal sample). For analytic simplicity, we removed multi-allelic 
mtDNA mutations and back mutations from the non-reference to the reference 
allele. After this filtration step, we obtained 10,083 somatic substitution candidates.
Second, we examined DNA cross-contamination because even minor DNA 
cross-contamination (that is, contamination level < 3%) would generate many 
low-VAF false positive calls that are in fact germline polymorphisms from the 
contaminating sample. We tested whether mtDNA somatic mutations detected 
from a cancer sample show greater overlap with known mtDNA polymorphisms 
than expected from the overall average rate (73.5%; 3,922/5,337 substitutions) 
using the binomial test with a cutoff P < 0.01. From this step, we removed 96 
samples with evidence of DNA cross-contamination (harboring 935 known 
mutations out of 1,131 known mutation candidates).
Third, we examined the overall mtDNA substitution signatures in the 
96 possible mutation classes. We removed four samples with extremely high 
proportions of C>G substitutions with strong sequence context bias (at 
CpCpN>CpApN; most frequently at CpCpG>CpApG; Supplementary Fig. 2b).  
This spectrum is known to arise from artificial guanine oxidation during 
sequencing library preparation steps19 with low VAF (1–2%). We explicitly 
removed these samples from further analyses.
Then, we examined the possibility of false positive calls due to mismapping 
of reads from inherited nuclear mtDNA-like sequences (known as numts) not 
represented in the human reference genome18, especially when the specific numts 
regions were amplified in the cancer nuclear genome. These mutation candidates 
showed some specific features: (1) they appeared as highly recurrent mtDNA 
somatic mutations among multiple samples; (2) VAFs in mitochondria were only 
slightly higher than our 1% cutoff criteria; and (3) the matched normal samples 
also had small but substantial numbers of mutation allele counts. To remove these 
false positive calls, we applied two statistical tests of: (1) whether the VAF of a 
mutation candidate in the matched normal sequences was within the normal range 
(<0.0024; the cutoff is determined by the median VAF of all mutation candidates 
+2× the interquartile range); and (2) whether:
Nmutnor=RDnor
ðNmutnor=RDnor þ Nmuttum=RDtumÞ
was within the normal range (<0.0357; the cutoff is determined by the median VAF 
of all mutation candidates +2× the interquartile range), where Nmut is the mutation 
allele count, RD is the average read depth for the nuclear genome, and nor and tum 
are normal and matched tumor tissues, respectively. When a mutation appeared 
to be an outlier according to both criteria, we removed the candidate from our 
downstream analyses.
In our previous study9, we could not detect mutations under a 3% VAF cutoff 
because mtDNA was sequenced with a read depth of ~100× from the majority 
of samples surveyed. Taking advantage of the ultra-high depth (>8,000×) in 
this study, we used a 1% VAF cutoff to obtain better sensitivity. We found 2,133 
more substitutions when the VAF was between 1 and 3%. Because of the ultra-
high depth, even 1% VAF mutations were considered to be specific, and were 
supported by a high number (n = ~80) of mutation alleles. We confirmed the high 
specificity of these mutations using the unique mtDNA mutational signatures 
robustly observed even from these low-VAF mutations: (1) the mutational 
spectrum is generally consistent with those from higher heteroplasmic levels of 
mutations (that is, VAFs from 3–10% and 10–100%); (2) we observed the absolute 
dominance of C>T and T>C substitutions in the expected trinucleotide contexts 
(NpCpG for C>T and NpTpC for T>C substitutions); and (3) we also observed 
extreme replication strand bias (Supplementary Fig. 3). These features would not 
be observed if contaminations resulted in many false positive calls. To assess the 
factors affecting the mutation frequency of the 13 coding genes, we performed the 
sample-level analysis using log-linear modeling: we assigned the binary mutation 
indicator (1: with mutation; 0: without mutation) to each sample for each gene 
and then fit this binary response variable to a logistic regression model, including 
cancer type, gene identity and their interaction as explanatory variables, which 
were later summarized using ANOVA. In addition, within each cancer type, we 
used Spearman’s rank correlation to assess the association between the numbers 
of nuclear and mtDNA somatic mutations, as well as their individual association 
with patient age.
Truncating mutation analysis. Taking into account the mtDNA-specific 
mutational signature, we examined the dN/dS ratio for mtDNA missense 
substitutions as reported previously9. We defined truncating mutations as those 
that lead to truncated protein products (that is, nonsense mutations and frameshift 
indels), and accordingly categorized the samples into the truncating group 
(bearing at least one truncating mutation with VAF ≥ 60%). The ND5 protein 
domain information was obtained from Pfam (http://pfam.xfam.org/protein/
P03915). The cancer gene census list was obtained from http://cancer.sanger.
ac.uk/cosmic/download. Cancer census genes with recurrent somatic mutations 
in kidney chromophobe and kidney papillary cancers were selected for analysis 
of mutual exclusivity and heat-map representation. One sample with a nuclear 
DNA hypermutator phenotype was excluded from this analysis. To examine the 
functional consequences of mtDNA truncating mutations, we performed GSEA 
based on the ranks of differentially expressed genes between samples with and 
samples without mtDNA truncating mutations for kidney chromophobe, kidney 
papillary, colorectal and thyroid cancers and their combination, and identified 
significantly enriched pathways at FDR = 0.05.
SMNT analysis. We examined the WGS data from the cancer and matched control 
tissue samples using a pipeline for the identification of mtDNA translocation to the 
nuclear genome, as reported previously11. The specificity was shown to be 100% 
in the previous study11. Briefly, we extracted and clustered discordant reads from 
cancer genomes, where one end aligned to nuclear DNA and the other aligned to 
mtDNA. Then, to determine the nucleotide resolution breakpoints, we searched 
for split reads near putative breakpoint junctions (1,000 base pairs upstream and 
downstream), where a fraction of a single read aligned to genomic DNA near the 
junctions and the rest aligned to mtDNA. All filtering criteria were the same as 
previously reported, except that we did not use BLAT51 for split-read detection 
because the BWA-MEM alignment tool used to map all pan-cancer samples 
fundamentally enables split-read mapping. We removed candidate mitochondrion–
nuclear DNA junctions that overlapped with clusters from matched and 
unmatched normal samples and/or known human SMNTs—a combined set from 
the human reference genome (hg19; n = 123) and a published study52 (n = 766)—
because the source of the mtDNA sequence fused to the nuclear genome might be 
SMNTs rather than real mitochondria in the cytoplasm of cells. We obtained the 
PCAWG Structural Variation Working Group16 and compared the samples with 
and without SMNTs by t-test. To study the relationship of SMNTs and structural 
variant breakpoints, we randomly chose the same number of structural variant 
breakpoints from each sample 100 times to estimate the random expectation.
MtDNA copy-number analysis. To better estimate the mtDNA copy number for 
cancer samples, we employed the following formula, which incorporates both 




ðf ´ ploidycancer þ ð1� f Þ ´ 2Þ
where f is the tumor purity (ranging from 0 to 1, where 1 stands for pure cancer 
cells and 0 stands for pure normal cells), CN is the mtDNA copy number, 
coverage_depthmtDNA and coverage_depthgDNA are the mean coverage depths for 
mtDNA and the nuclear genome in individual WGS BAM files, respectively, and 
ploidycancer is the number of sets of chromosomes in tumor cells, while ploidy in the 
normal cells is 2. Both f and ploidycancer were obtained using allele-specific copy-
number analysis of tumors estimation53, provided by the PCAWG Consortium. 
Donors with multiple samples were preselected so that each donor came with one 
representative primary cancer sample. We excluded cancer samples with low purity 
(<0.4, estimated by allele-specific copy-number analysis of tumors) for further 
downstream analyses. We used ANOVA (if there were more than two cancer types) 
or t-test to compare the mtDNA copy number of cancer types derived from the 
same tissue. Since many of the normal samples were from blood, we focused on the 
cancer types with at least ten samples from the normal tissue adjacent to the tumor 
in order to compare the mtDNA copy number of the paired cancer and normal 
samples. We used the Wilcoxon signed-rank test to compare the mtDNA copy 
number for each selected cancer type and further adjusted the raw P values based 
on the FDR. To assess the correlation of mtDNA copy number with truncating 
mutations, we employed ANOVA (with the cancer type included in the model, 
to account for its potential effect). We assessed the correlations of the mtDNA 
copy number with the patient’s age, overall survival time and cancer stage using 
Spearman’s rank correlation, Cox model/log-rank test and ANOVA, respectively. 
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We log2-transformed the mtDNA copy-number values when using ANOVA and 
the t-test, to conform to the normality assumption.
mtDNA structural variation analysis. To investigate large deletions or 
duplications in the mtDNA genome, we sought the read-depth change of tumor 
mtDNA sequences using normal mtDNA sequences as a reference. To this end, 
we calculated the normalized depth of mtDNA loci in 100-base pair-sized bins 
from all of the normal samples. Then, we calculated the deviation of mtDNA 
read depth in each tumor sample. When ten bins were consecutively increased 
or decreased in the relative depth sufficiently (z score > 3), we considered the 
region as a structural variation candidate. From all of the candidates, we sought 
discordant paired-end reads, or breakpoint-spanning reads, which strongly 
support structural variations11.
Co-expression analysis. For each cancer type, we used the WGCNA package41 
to build a weighted gene co-expression network that contains ~20,000 nodes 
(including both nuclear genes and mitochondrial genes). The key parameter, 
β, for a weighted network construction was optimized to maintain both the 
scale-free topology and sufficient node connectivity, as recommended in the 
manual. In such a network, any two genes were connected and the edge weight 
was determined by the topology overlap measure provided in WGCNA. This 
measure considered not only the expression correlation between two partner 
genes, but also how many ‘friends’ the two genes shared. The weights ranged 
from 0 to 1, which reflected the strength of the connection between the two 
genes. To identify mitochondria-related pathways, we performed GSEA42 on the 
basis of the full set of nuclear protein-coding genes, ranked on the basis of the 
weights of the edge connecting the mitochondrial genes, and detected significant 
pathways at FDR = 0.05. To construct the mitochondria-centric network, we 
focused on the top 500 neighboring genes that showed the strongest connections 
with the mitochondrial genes, with a minimum weight of 0.05. Among these 
neighboring genes, we detected the clinically actionable genes (defined as  
FDA-approved therapeutic targets and their relevant predictive markers54)  
in at least one of the cancer types we surveyed. We examined the correlations 
of mtDNA gene expression levels with mtDNA copy numbers using Spearman’s 
rank correlations.
TCMA data portal construction. We stored the precalculated mtDNA molecular 
data (including mtDNA mutation, nuclear transfer, copy number and expression) 
in a database of CouchDB. The Web interface was implemented by JavaScript, 
tables were visualized by DataTables, and the co-expression network visualization 
was implemented by Cytoscape Web.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Somatic and germline variant calls, mutational signatures, subclonal 
reconstructions, transcript abundance, splice calls and other core data generated 
by the ICGC/TCGA PCAWG Consortium are described here14 and are available 
for download at https://dcc.icgc.org/releases/PCAWG. Additional information 
on accessing the data, including raw read files, can be found at https://docs.icgc.
org/pcawg/data/. In accordance with the data access policies of the ICGC and 
TCGA projects, most molecular, clinical and specimen data are in an open tier 
that does not require access approval. To access information with the potential 
to identify individuals, such as germline alleles and underlying sequencing data, 
researchers will need to apply to the TCGA Data Access Committee via the 
Database of Genotypes and Phenotypes (https://dbgap.ncbi.nlm.nih.gov/aa/wga.
cgi?page=login) for access to the TCGA portion of the dataset, and to the ICGC 
Data Access Compliance Office (http://icgc.org/daco) for the ICGC portion. In 
addition, to access somatic single-nucleotide variants derived from TCGA donors, 
researchers will also need to obtain Database of Genotypes and Phenotypes 
authorization. Derived datasets described specifically in this study are available 
from the TCMA data portal (http://bioinformatics.mdanderson.org/main/
TCMA:Overview).
Code availability
The core computational pipelines used by the PCAWG Consortium for alignment, 
quality control and variant calling are available to the public at https://dockstore.
org/search?search=pcawg under GNU General Public License version 3.0, which 
allows for reuse and distribution.
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